| Document |
Document Title |
|
WO/2024/040036A2 |
The present disclosure relates to treatment of a subject who has been identified with an increased IRF4 gene expression or infiltration of MUM-1+ cells. The present disclosure also relates to treatment of a subject who has been identifie...
|
|
WO/2024/038088A1 |
The present invention provides an aqueous liquid composition comprising a conjugate of hyaluronan and a pharmaceutically active compound, and a sugar or sugar alcohol, wherein the concentration of the sugar or sugar alcohol in the compos...
|
|
WO/2024/040095A2 |
The invention provides pharmaceutical compositions comprising molecules capable of disassembling tau amyloid fibrils or alpha-synuclein amyloid fibrils, as well as methods for making compositions comprising these molecules. Embodiments o...
|
|
WO/2024/038087A1 |
The present invention provides a method for the preparation of a sterile composition comprising a conjugate of sodium hyaluronate or hyaluronic acid and a pharmaceutically active compound, comprising: providing a conjugate of sodium hyal...
|
|
WO/2024/039203A1 |
The present invention relates to a magnetic torquer (m-Torquer) conjugant-based drug. Specifically, according to the present invention, an m-Torquer conjugant having (a) magnetic nanoparticles that generate torque upon application of a c...
|
|
WO/2024/040119A2 |
Compositions and methods for safe and effective treatment for cardiac arrhythmias via increasing [K+]o and administering a sodium channel blocker are disclosed. In certain embodiments, the method includes administering a composition comp...
|
|
WO/2024/036094A2 |
Methods for facilitating the genesis of photoreceptor rods in a subject by administering a therapeutically effective amount of a therapeutic agent are provided. Other methods are provided for treating retinitis pigmentosa by administerin...
|
|
WO/2024/033540A1 |
The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic lipid compound comprising a phospholipid, a fluorinated compound...
|
|
WO/2023/038927A9 |
Provided herein are methods for treatment of bladder cancer, such as non-muscle invasive bladder cancer, by targeted injection of a therapeutic agent to the lamina propria of the bladder wall that comprises or is proximate to a bladder c...
|
|
WO/2024/036279A2 |
The present disclosure provides methods of preparing compositions comprising a collection of biological polymers using an additive manufacturing techniques to create a final pharmaceutical composition or device. These methods comprise st...
|
|
WO/2024/036114A2 |
Provided herein, inter alia, are compositions and methods comprising combination therapies including a BRAE axis inhibitor and a COX-2 inhibitor for the treatment of cancer. In embodiments, the combination therapies further include an EG...
|
|
WO/2024/033546A1 |
Magnetic polymer nanocapsules and their use in anti-cancer therapy have been disclosed, which are core-shell polymer nanocapsules carrying hydrophobic active substances, containing magnetic iron oxide nanoparticles.
|
|
WO/2024/026841A1 |
Provided are a drug-loaded erythrocyte membrane nanoparticle, a method for preparing same, and use thereof. The drug-loaded erythrocyte membrane nanoparticle is loaded with an anion reaction precursor and a cation reaction precursor. An ...
|
|
WO/2024/028411A1 |
The present disclosure relates to combinations of cyclin-dependent kinase 7 (CDK7) inhibitors and other therapeutic treatments, in particular other anti-cancer agents, and uses of such combination(s) in the treatment of cancers.
|
|
WO/2024/031030A2 |
A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRDl-like family, of the subject to a preset standard level. The DRD1/5 level and expression ca...
|
|
WO/2024/026354A2 |
Provided herein are compositions and methods of use thereof for treating Autosomal recessive polycystic kidney disease (ARPKD) by targeting RAC1 and/or FOS.
|
|
WO/2024/026458A2 |
Disclosed herein is a method of treating cancer in a subject that includes administering to a subject having a cancer an inhibitor of glycogen metabolism under conditions effective to treat the cancer, wherein the cancer is characterized...
|
|
WO/2024/026400A2 |
This disclosure relates to therapeutic combinations of TITR effectors such as CCR8 targeting agents, radiation therapy and checkpoint inhibitors and methods of using the same for the treatment of cancer. The disclosure also relates to me...
|
|
WO/2024/026505A2 |
The present disclosure is drawn to compositions, combinations of compounds, and methods of treating a cancer or neoplasia, including disrupting activity of telocytes associated with the cancer.
|
|
WO/2024/019441A1 |
The present invention relates to the fusion technology of cell-derived vesicles and liposomes, and hybrid nanoparticles fabricated by the fusion technology, wherein the hybrid nanoparticles can exhibit both a specific tissue-targeting fu...
|
|
WO/2024/019542A1 |
The present invention relates to ultrasonic-responsive porphyrin-liposomes capable of releasing drugs in response to ultrasound. The ultrasonic-responsive porphyrin-liposomes of the present invention contain porphyrin. When exposed to ul...
|
|
WO/2024/018415A1 |
The invention relates to a pharmaceutical formulation comprising 5-aminolevulinic acid and/or the salts thereof and a poloxamer-based carrier for use in the treatment of pancreatic cancer by intralesional application and irradiation with...
|
|
WO/2024/019978A2 |
The invention provides methods and compositions for treating food related disorders, as well as methods for enhancing the therapeutic activity of a stimulant and methods for lowering the amount of a stimulant required to achieve a therap...
|
|
WO/2024/020302A2 |
Methods of treating a metabolic disorder in a subject are provided. Aspects of the method include enhancing extracellular Carboxylesterase 2 (CES2) activity in the subject in order to treat the subject for the metabolic disorder. Also pr...
|
|
WO/2024/017917A1 |
The invention relates to an apparatus (21) for the treatment, by electromagnetic irradiation at a predetermined dose, of a biological fluid contained in an irradiation receptacle, the irradiation receptacle having at least one wall which...
|
|
WO/2024/020553A2 |
Described herein are pharmaceutical compositions for melatonin receptor agonists for use in tissues outside of the CNS. Also described herein are methods for using the pharmaceutical compositions described herein for improving menopausal...
|
|
WO/2024/020427A2 |
A novel 7-marker metabolite panel (7MetP) comprising or consisting of diacetylspermine, diacetylspermidine, N-(3-acetamidopropyl)pyrrolidin-2-one, Nacetylneuraminate, N-acetyl-mannosamine, N-acetyl-lactosamine, and hydroxyisobutyric acid...
|
|
WO/2024/020092A2 |
Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitors and their use in treating or preventing cardiovascular diseases are disclosed.
|
|
WO/2024/013272A1 |
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an effici...
|
|
WO/2024/015484A2 |
Provided herein are methods and systems for determining and/or validating response to a checkpoint kinase 1 (Chkl) inhibitor, a Weel inhibitor, an ATR inhibitor, or a combination thereof, and methods of administering a Chkl inhibitor, a ...
|
|
WO/2024/015934A2 |
Adenomyosis is a highly prevalent yet enigmatic disease that can be diagnosed only via histopathology among women undergoing hysterectomy, thus, leading to underdiagnosis. Unfortunately, research on adenomyosis has been limited due to a ...
|
|
WO/2024/015761A2 |
The present disclosure relates to compounds, and methods of use thereof, useful for the treatment of airway disease in a subject. In one aspect, the present disclosure relates to a method of treating, preventing, and/or ameliorating an a...
|
|
WO/2024/014325A1 |
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin co...
|
|
WO/2024/014624A1 |
The present invention relates to a photothermal microneedle patch containing gold nanoparticles. The patch of the present invention is a patch in which a skin-soluble microneedle containing a drug or a cosmetic composition is formed on a...
|
|
WO/2024/015951A2 |
Provided are methods for identifying biomarkers associated with Alzheimer's disease. Also provided are methods for treating Alzheimer's disease by antagonizing or agonizing pathways identified by the disclosed methods.
|
|
WO/2024/012071A1 |
Provided in the present invention is a preparation method for a nano-enzyme inducing generation of reactive oxygen species under light regulation. The preparation method comprises the following steps: separately weighing proper amounts o...
|
|
WO/2024/015880A2 |
The disclosure is related to a method of treating a non-genetic obesity (e.g., hypothalamic obesity) in a subject using a melanocortin-4 receptor (MC4R) agonist.
|
|
WO/2024/007859A1 |
A gambogic acid-loaded mesoporous nanoparticle, a preparation method therefor and a use thereof in cancer treatment, relating to the technical field of medicines. The gambogic acid-loaded mesoporous nanoparticle is prepared from the foll...
|
|
WO/2024/011258A2 |
Disclosed are apparatus, compositions, and methods for promoting regeneration of tissue on a subject such as a wounded, damaged, or injured appendage, or within a subject such as a wounded, damaged, or injured organ. The disclosed appara...
|
|
WO/2024/006796A2 |
The instant disclosure relates to compositions and methods that include NOX4 inhibitors as therapeutic agents capable not only of reducing fibrosis in muscle tissues of subjects having or at risk of developing a muscular dystrophy but al...
|
|
WO/2024/006292A2 |
The present disclosure relates to methods and compositions for the treatment of cancer.
|
|
WO/2024/006965A1 |
Monoclonal antibodies that specifically bind CD25, as well as conjugates of the anti-CD25 antibodies, are described. The CD25-specific monoclonal antibodies and conjugates thereof do not block binding of IL- 2 to CD25 and induce little t...
|
|
WO/2024/006804A2 |
Provided herein are methods of preventing or treating a tumor in a subject in need thereof, comprising administering to the subject a dose of a stimulator of interferon genes protein (STING) agonist, wherein the amount of the STING agoni...
|
|
WO/2024/006841A2 |
Disclosed herein among other things are methods of inducing anesthesia, sedation, and methods for treating diseases and disorders including central nervous system disorders, traumatic brain injuries, peripheral nervous system disorders, ...
|
|
WO/2024/007015A2 |
Provided herein are rearranged during transfection (RET) fusion nucleic acid molecules and RET fusion polypeptides, methods related to detecting RET fusion nucleic acid molecules and RET fusion polypeptides in cancer, as well as methods ...
|
|
WO/2024/006994A2 |
Provided herein are compositions and method for the treatment of cancer by inhibiting expression of the breast cancer gene 1 pseudogene 1 (BRCA1P1). In particular, provided herein are nucleic acid inhibitors of BRCA1P1 and methods of use...
|
|
WO/2023/245857A1 |
Disclosed in the present invention are a capsaicin-derived photosensitizer, and a preparation method therefor and the use thereof. In the photosensitizer, bodipy is used as a mother nucleus, the maximum absorption peak of bodipy red-shif...
|
|
WO/2023/248085A1 |
Systems and methods are disclosed for inducing apoptosis and treating or reducing the occurrence of at least one condition, disease, disorder, or infection in a subject. The systems and methods rely on the application of an alternating e...
|
|
WO/2023/248744A1 |
Provided is a treatment method that provides a better response rate and/or life-extending effectiveness in nonhuman mammals with cancer. Provided are: a method for treating cancer in non-human mammals, the method comprising starting tr...
|
|
WO/2023/250291A2 |
The present disclosure provides methods of treating corneal disorders with modulators of the WNT signalling pathway. More particularly, provided are treatments for cornea epithelial and/or endothelial injuries, defects, deficiencies, and...
|
